Pablo M. Tebas

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

Journal: Research square

Published: July 10, 2026

Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.

Journal: bioRxiv : the preprint server for biology

Published: June 22, 2026

Are screening periods in ART-naive trials justified in the era of rapid ART?

Journal: The lancet. HIV

Published: April 15, 2026

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 17, 2025

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 17, 2025

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 17, 2025

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Journal: Lancet (London, England)

Published: August 04, 2025

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 17, 2025

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 18, 2025

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 18, 2025

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.

Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.

Are screening periods in ART-naive trials justified in the era of rapid ART?

Are screening periods in ART-naive trials justified in the era of rapid ART?

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.

Understanding the clinical implications of low-level viremia in ART-treated individuals.

Understanding the clinical implications of low-level viremia in ART-treated individuals.

Future of bNAbs in HIV Treatment.

Future of bNAbs in HIV Treatment.